Back
Speaker illustration

Doctor Thomas Mondritzki

Bayer AG, Wuppertal (Germany)

Member of:

European Society of Cardiology

Presentations Articles

Real-world evidence for patient phenotypes in heart failure with preserved ejection fraction

Event: ESC Congress 2024

Topic: Epidemiology, Prognosis, Outcome

Session: Heart failure therapy: new insights

Access
Like
Thumbnail

Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor

Event: Heart Failure 2018

Topic: Experimental Heart Failure

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Access
Like
Thumbnail

Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?

Event: ESC Congress 2016

Topic: Pharmacologic therapy

Session: Heart failure / Left ventricular dysfunction

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources